Evidence map›Paper›PMID 34356875›Full record

ArticleBiomedicines2021

Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib.

Michele Manganelli, Ilaria Grossi, Manuela Ferracin, Paola Guerriero, Massimo Negrini, Michele Ghidini, Chiara Senti, Margherita Ratti, Claudio Pizzo, Rodolfo Passalacqua and 6 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. World journal of gastroenterology · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Epigenetic remodelling in human hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Michele ManganelliDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-8219-0252
Ilaria GrossiDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-7768-0794
Manuela FerracinDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-1595-6887
Paola GuerrieroDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy.
Massimo NegriniDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy.
Michele GhidiniDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy.
Chiara SentiDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy.
Margherita RattiDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy.
Claudio PizzoDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy.
Rodolfo PassalacquaDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, Italy.
Sarah MolfinoDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy.
Gianluca BaiocchiDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-2402-2178
Nazario PortolaniDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, Italy.
Eleonora MarchinaDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-1672-1908
Giuseppina De PetroDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9306-0851
Alessandro SalviDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-6993-1565
University of Brescia · ITIstituti Ospitalieri di Cremona · ITUniversity of Ferrara · ITUniversity of Bologna · IT

Funding

Consorzio Interuniversitario Biotecnologie CIB_2020FFRB AS-2018Fondazione Ente Universitario Lombardia Orientale eulo_2019Ricerchiamo Onlus IG_2018
6 · The paper itself

Abstract

Human hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness to treatment are needed. In this work, we performed an exploratory study to investigate the longitudinal levels of cell-free long ncRNA GAS5 and microRNAs miR-126-3p and -23b-3p in a cohort of 7 patients during the period of treatment with sorafenib. We used qPCR to measure the amounts of GAS5 and miR-126-3p and droplet digital PCR (ddPCR) to measure the levels of miR-23b-3p. Patients treated with sorafenib displayed variable levels of GAS5, miR-126-3p and miR-23b-3p at different time-points of follow-up. miR-23b-3p was further measured by ddPCR in 37 healthy individuals and 25 untreated HCC patients. The amount of miR-23b-3p in the plasma of untreated HCC patients was significantly downregulated if compared to healthy individuals. The ROC curve analysis underlined its diagnostic relevance. In conclusion, our results highlight a potential clinical significance of circulating miR-23b-3p and an exploratory observation on the longitudinal plasmatic levels of GAS5, miR-126-3p and miR-23b-3p during sorafenib treatment.

Indexed as

ddPCRGAS5HCCmiR-126-3pmiR-23b-3psorafenib

Identifiers

PMID34356875
PMCPMC8301380
OpenAlexW3180006686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.